Castleman Disease Collaborative Network Biobank

Withdrawn

• Conditions: Angiofollicular Lymphoid Hyperplasia; GLNH; Giant Lymph Node; Castleman's Disease; Giant Lymph Node Hyperplasia; Angiofollicular Lymph Hyperplasia; Angiofollicular Lymph Node Hyperplasia; Castleman Disease; Hyperplasia
• Interventions: Other: Sample Collection

• Registration Number: NCT02871050
• Lead Sponsor: Castleman Disease Collaborative Network

Brief Summary

The purpose of this study is to create a biobank, which collects, stores, and distributes samples of human tissues, blood, and related health information to qualified scientists, in order to help doctors and researchers better understand why Castleman Disease occurs and develop ways to better treat and prevent it.

Detailed Description

The CDCN proposes to establish a biobank and associated clinical data for Castleman disease. Tissue and fluid (blood and saliva) samples will be collected both prospectively and retrospectively. Blood or saliva samples may also be collected from relatives of Castleman patients. Because of the scarcity of these samples, it will be necessary to make efforts to access all available cases. Many cases will occur at hospitals that do not have an existing relationship with the CDCN and may not have experience with tissue procurement; however, this is the only way to obtain the vast majority of samples. Samples may be used immediately, banked for future use, or further processed into DNA, cell lines, tissue microarrays, etc.

The samples will be stored at Precision for Medicine, a biorepository company that specializes in collection, processing, storage and distribution of biospecimens. Only researchers (US or international) who have applied to the CDCN and have been approved by the Biobank Advisory Board will be eligible to access biospecimens and/or data. The Biobank Advisory Board will be comprised of clinicians and scientists with experience in clinical and investigational practices in Castleman Disease.

Study Timeline

• Study Start: 2016-06
• Study First Submitted: 2016-08-15
• Study First Submitted QC: 2016-08-17
• Study First Posted: 2016-08-18
• Primary Completion: 2018-06
• Study Completion: 2018-06
• Status Verified: 2018-07
• Last Update Submitted: 2018-07-28
• Last Update Posted: 2018-07-31

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Castleman Disease Patients	Sample Collection	Potential study participants may be of any age, gender, or ethnicity who have been diagnosed with Castleman disease.

Primary Outcome Measures

Name	Time	Method
Samples Collected	3 years	Number of samples collected across different subgroups (e.g. blood products, lymph node)

Trial Locations

Locations (1)

Castleman Disease Collaborative Network; 🇺🇸 Philadelphia, Pennsylvania, United States